PubMed Health⌕ Search

PubMed · 16618190

From exponential to linear growth in polyelectrolyte multilayers.

Abstract

There exist two types of polyelectrolyte multilayers: those whose thickness increases linearly with the number of deposition steps, which are nicely structured, and those whose thickness increases exponentially, which resembles hydrogels. This simple picture has recently slightly evolved with the finding that some exponentially growing films enter into a linear growth phase after a certain number of deposition steps. In this study, we investigate the buildup process of hyaluronic acid/poly(L-lysine) (HA/PLL) multilayers that constitute one of the best known exponentially growing systems. The films are built by using two deposition methods: the well-known dipping method and the more recent spraying method where the polyelectrolyte solutions are sprayed alternately onto a vertical substrate. The goal of this study is twofold. First, we investigate the influence of the main parameters (i.e., spraying rate and spraying time) of the spraying method on the film growth process. We find that, as for the dipping method, the film thickness first evolves exponentially with the number of deposition steps, and after a given number of deposition steps, it follows a linear evolution. We find that similar behavior is observed with the dipping method. Second, because the spraying method allows the very fine variation of the different parameters of the buildup, we use this method to investigate the exponential-to-linear transition. We find that this transition always takes place after about 12 deposition steps whatever the values of the parameters controlling the deposition process. We discuss our results in light of a model proposed by Hübsch et al. (Hübsch, E.; Ball, V.; Senger, B.; Decher, G.; Voegel, J. C.; Schaaf, P. Langmuir 2004, 20, 1980-1985) and later by Salomäki et al. (Salomäki, M.; Vinokurov, I. A.; Kankare, J. Langmuir 2005, 21, 11232-11240) in which it is assumed that the exponential-to-linear transition is due to a film restructuring that progressively forbids the diffusion of one of the polyelectrolytes constituting the film over part of the film. This "forbidden" zone then grows with the number of deposition steps so that the outer zone of the film that is still concerned with diffusion keeps a constant thickness and moves upward as the total film thickness increases.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Claudine Porcel, Philippe Lavalle, Vincent Ball, Gero Decher, Bernard Senger, Jean-Claude Voegel, Pierre Schaaf. 2006-04-25. From exponential to linear growth in polyelectrolyte multilayers.. https://doi.org/10.1021/la053218d

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗